Literature DB >> 17992590

A conspicuous role for B cells In Sjögren's syndrome.

Pierre Youinou1, Valérie Devauchelle, Pascal Hutin, Rozenn Le Berre, Alain Saraux, Jacques-Olivier Pers.   

Abstract

Although the relative contributions of T cells and B cells in Sjögren's syndrome (SS) are far from being settled, recent studies have suggested a crucial role for B cells in its pathophysiology. Early investigations have focused on the ability of B cells to produce autoantibodies, and new studies have enlarged the range of their functions. For example, beyond the paradigm that T lymphocytes maintain strict control over B cells, the latter cells are now acknowledged to solicit their own help from the former cells and release a flurry of cytokines. Further, some of these B cells act as antigen-presenting cells. Increased levels of the B cell activating factor (BAFF) found in SS may be responsible for high numbers of circulating Bm2/Bm2' cells and associated functional abnormalities of B cells, such as a BAFF-induced increased expression of CD19, which decreases the required strength generated by antigen binding for transmitting its signal. This review reports compelling evidence that B cells are involved in the pathophysiology of SS. As this brings novel prospects for the treatment of the disease, it is no surprise that B cell ablative treatment has proven to be relatively efficacious in SS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17992590     DOI: 10.1007/s12016-007-8000-y

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  79 in total

1.  IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome.

Authors:  B Bendaoud; Y L Pennec; A Lelong; J F Le Noac'h; G Magadur; J Jouquan; P Youinou
Journal:  J Autoimmun       Date:  1991-02       Impact factor: 7.094

Review 2.  Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going?

Authors:  Luke Dawson; Andrew Tobin; Peter Smith; Tom Gordon
Journal:  Arthritis Rheum       Date:  2005-10

3.  BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome.

Authors:  Frédérique d'Arbonneau; Jacques-Olivier Pers; Valérie Devauchelle; Yvon Pennec; Alain Saraux; Pierre Youinou
Journal:  Arthritis Rheum       Date:  2006-01

Review 4.  A case for regulatory B cells.

Authors:  Atsushi Mizoguchi; Atul K Bhan
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

5.  Increased N-linked glycosylation leading to oversialylation of monomeric immunoglobulin A1 from patients with Sjögren's syndrome.

Authors:  C Basset; V Durand; C Jamin; J Clément; Y Pennec; P Youinou; M Dueymes; I M Roitt
Journal:  Scand J Immunol       Date:  2000-03       Impact factor: 3.487

6.  Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome.

Authors:  Malin V Jonsson; Peter Szodoray; Stig Jellestad; Roland Jonsson; Kathrine Skarstein
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

Review 7.  The TNF family members BAFF and APRIL: the growing complexity.

Authors:  Fabienne Mackay; Christine Ambrose
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

Review 8.  B lymphocytes on the front line of autoimmunity.

Authors:  Pierre Youinou; Sophie Hillion; Christophe Jamin; Jacques-Olivier Pers; Alain Saraux; Yves Renaudineau
Journal:  Autoimmun Rev       Date:  2005-08-16       Impact factor: 9.754

9.  Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome.

Authors:  P Tengnér; A K Halse; H J Haga; R Jonsson; M Wahren-Herlenius
Journal:  Arthritis Rheum       Date:  1998-12

Review 10.  Transitional B cells: step by step towards immune competence.

Authors:  James B Chung; Michael Silverman; John G Monroe
Journal:  Trends Immunol       Date:  2003-06       Impact factor: 16.687

View more
  10 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

3.  Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.

Authors:  Jason S Ellis; Xiaoxiao Wan; Helen Braley-Mullen
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

4.  Loss of PKCδ results in characteristics of Sjögren's syndrome including salivary gland dysfunction.

Authors:  G P Banninger; S Cha; M S Said; K M Pauley; C J Carter; M Onate; B A Pauley; S M Anderson; M E Reyland
Journal:  Oral Dis       Date:  2011-06-27       Impact factor: 3.511

Review 5.  New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome.

Authors:  Anna K Bird; Nida Meednu; Jennifer H Anolik
Journal:  Curr Opin Rheumatol       Date:  2015-09       Impact factor: 5.006

6.  A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis.

Authors:  Ioannis Bellos; Ioannis Boletis; Sophia Lionaki
Journal:  Kidney Int Rep       Date:  2022-03-02

Review 7.  Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.

Authors:  Jennifer H Anolik; R John Looney; Frances E Lund; Troy D Randall; Iñaki Sanz
Journal:  Immunol Res       Date:  2009-04-07       Impact factor: 2.829

8.  Central role for marginal zone B cells in an animal model of Sjogren's syndrome.

Authors:  Long Shen; Chun Gao; Lakshmanan Suresh; Zhenhua Xian; Nannan Song; Lee D Chaves; Meixing Yu; Julian L Ambrus
Journal:  Clin Immunol       Date:  2016-04-30       Impact factor: 3.969

Review 9.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

10.  Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.

Authors:  Arjun Sharma; Jeremy Kiripolsky; Ekaterina Klimatcheva; Alan Howell; Farzad Fereidouni; Richard Levenson; Thomas L Rothstein; Jill M Kramer
Journal:  Clin Immunol       Date:  2016-01-28       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.